Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coronaviruses: Single-domain antibody
- Development stage
- Preclinical
- Lead developer
- Beroni Group
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intranasal, Inhalation, Intravenous, Subcutaneous, Transdermal
01
Overview
Coronaviruses: Single-domain antibody is a nanobody-based therapeutic candidate developed by Beroni Group in collaboration with Tianjin University for the treatment of SARS-CoV-2 (COVID-19) infections. The development program utilized a massive library of over one billion nanobody sequences to identify 24 high-affinity single-domain antibodies. Among these, 16 candidates specifically target the SARS-CoV-2 spike (S) protein, functioning as neutralizing agents to block viral entry into host cells. These nanobodies have undergone optimization and humanization to minimize immunogenicity while maintaining high specificity and binding affinity. As of the latest reports, the program is in preclinical development, with ongoing efforts focused on animal testing and preparation for clinical trials.
- Other names
- Coronaviruses: Single-domain antibodySARS-CoV-2 nanobodySARS-CoV2 nanobodySARS-CoV 2 nanobodyBeroni coronavirus nanobody
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Coronaviruses: Single-domain antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coronaviruses: Single-domain antibody.